声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 点击查看公告原文>> 在市场拓展时效上，产品进入新城市或新区域药店的见效时间，取决于药店的执行力与运营能力，重视 且运营能力强的药店2至3个月可见起色，反之则较慢。 烟民复吸率方面，服用酒石酸伐尼克兰片的烟民通常几天内可见效，但因尼古丁成瘾受生理和心理多种 因素影响，复吸原因众多，存在一定比例复吸情况，公司建议烟民按疗程服药。 对于辉瑞戒烟药若重新进入中国市场的影响，仟源医药认为，辉瑞强大的品牌影响力和市场推广能力， 会吸引更多消费者关注，提升戒烟药市场知名度，拓展并教育市场，做大市场蛋糕。 9月16日10:30 - 11:30，山西仟源医药集团股份有限公司通过线上电话会的形式，接受了博时基金、申万 ...

Group 1: Sales Channels and Performance - The company’s smoking cessation drug, Varenicline Tartrate Tablets, utilizes a dual-brand strategy (PariKe and Family Pharmacist) and multiple sales channels, including over 100,000 chain stores and more than 600 hospitals, with online sales primarily through JD, Alibaba, and Meituan [2] - The largest sales volume for the smoking cessation drug currently comes from offline chain channels [2] - Sales in hospital channels have not met company expectations, as most hospitals only have smoking cessation clinics available for one or two half-days a week [3] Group 2: Market Expansion and Effectiveness - The time required to see results from expanding the drug to new cities or regions depends on the pharmacy's execution; well-managed pharmacies may show improvement in 2 to 3 months, while others may take longer [3] - Smokers using Varenicline Tartrate Tablets generally see effects within a few days, but a significant proportion experience relapse due to various physiological and psychological factors [3] Group 3: Competitive Landscape - If Pfizer re-enters the Chinese market with its smoking cessation drug, the company believes it would positively impact the market by increasing consumer awareness and expanding the overall market size [3]

Market Expansion - As of June 2025, the company's smoking cessation drug, varenicline tartrate tablets, has entered over 100,000 retail stores in the OTC market, with a target of exceeding 140,000 stores by the end of 2025 and 250,000 stores by the end of 2026 [2][3] Market Capacity - The smoking cessation drug market in China has a significant potential, with over 300 million smokers, and the company aims to cover 50 million smokers over the next 10 years [2] User Demographics - The user demographic for varenicline tartrate tablets spans all age groups, with the highest proportion being male smokers in their 30s [3] Cost of Treatment - The estimated cost for each smoker using the varenicline tartrate tablets for a 3-month treatment course is no more than RMB 2,000 [3] Shareholding and Future Plans - The company acknowledges that its major shareholders have a relatively low holding percentage and plans to promote a stock issuance project to specific investors [3]